Generalized depletion of free nerve endings and decrease of cutaneous nervous innervation in streptozotocin-induced painful and painless diabetic rats  by Chu, Chi-Chun et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 75 (2012) 314e321
www.jcma-online.comOriginal Article
Generalized depletion of free nerve endings and decrease of cutaneous
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Received November 3, 2011; accepted February 24, 2012AbstractBackground: The loss of peripheral nerve fiber is evident in chronic painful diabetic neuropathy. However, the correlation between peripheral
fiber loss and the genesis of pain is unclear. Using the streptozotocin-induced diabetic rat model and focusing on free nerve endings, we
attempted to investigate the peripheral changes that elicit pain syndromes in diabetes.
Methods: Diabetes was induced in rats using 75 mg/kg streptozotocin, while controls received saline solution. “Painful” rats with thermal or
mechanical hypersensitivity and “painless” rats (without significant threshold changes) were enrolled. The peripheral nerve endings were
immunostained using protein gene product 9.5 in footpad skin sections. The peripheral nerve densities in each behavior group were calculated
and averaged.
Results: A progressive loss of protein gene product 9.5-blotted nerve fibers was noted after diabetes was induced and as the duration of
hyperglycemia proceeded. Painful and painless diabetic rats have similar histological nerve fiber loss including depleted epidermal free nerve
endings.
Conclusion: The results indicated that there are undiscovered pathological changes that are sensitizing the injured nerve fiber in periphery.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Painful diabetic neuropathy (PDN) is a common compli-
cation of both type 1 and type 2 chronic diabetes. Although its
pathophysiology is not clear, most authors believe PDN to be
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http://dx.doi.org/10.1016/j.jcma.2012.05.005focusing on certain classes of peripheral nerve fibers or
morphological differences failed to find a correlation between
pain generation and peripheral nerve dysfunction in diabetic
patients.4e6
In recent years, the cutaneous free nerve ending (FNE) has
been increasingly studied in peripheral neuropathic disorders,
including diabetic neuropathy. These FNEs are unmyelinated
sensory nerve fibers terminating in the epidermaledermal
junction.7 These nerve terminals may play pain-perceptive
roles which involve responses to thermal, mechanical, chem-
ical, and nociceptive stimuli.8,9 The cutaneous FNEs havehinese Medical Association. All rights reserved.
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neurotransmission induced by nociceptive stimuli,10 and are
putatively able to induce nociception by sensory sensitiza-
tion.11 Although it is highly likely that these FNEs play a role
in triggering PDN, the correlation between cutaneous FNEs
and the pathogenesis of PDN remains unclear.
In order to examine the mechanisms contributing to pain
genesis, we investigated the peripheral changes in PDN. First,
by using the pan-neural marker protein gene product 9.5 (PGP
9.5)12 and the widely used streptozotocin (STZ)-induced PDN
model,13,14 we estimated the changes in PGP 9.5 innervation
density using immunohistochemical analysis through the dia-
betic course. Second, we recorded behavior changes including
thermal hyperalgesia, mechanical allodynia, and painless
(those without significant threshold changes) in diabetic rats.
Last, we examined the density of PGP 9.5 in the footpad skin
from different behavioral phenotypes in diabetic rats to
elucidate the underlying changes.
2. Methods2.1. Diabetic animal modelThis study was approved by the Animal Care Ethics
Committee of the National Defense Medical Center (IACUC-
05-031) and was conducted according to the guidelines of the
Ethics Committee of the International Association for the Study
of Pain. Experimental diabetes was induced in male Spra-
gueeDawley rats weighing 250e300 g by a single intraperi-
toneal injection of 75 mg/kg STZ (Sigma-Aldrich, St. Louis,
MO, USA) to achieve a maximal induced diabetic ratio and to
maintain a stable, chronic hyperglycemic state. The rats in the
control group were of the same gender and weight, and received
intraperitoneal saline. Blood glucose levels were checked for 7
consecutive days following STZ injection and at every interval
after behavior testing. Glucose was measured with a glucose
meter (ADVANTAGE, Roche, Nutley, NJ, USA) using whole
blood taken from the ventral tail vein under isoflurane anes-
thesia. Diabetes was confirmed by a persistently elevated blood
glucose level greater than 270 mg/dL (15 mM). All rats were
maintained in plastic-bottomed cages covered with sawdust
bedding and given free access to sufficient food and water.
Colony cages were cleaned daily and were kept on a 12-hour
lightedark cycle at 22C, with an independent air supply.
Diabetic rats with body weight that fell below 200 g, ceased
significant exploratory activities, or had obvious evidence of
infection were excluded from the study and were euthanized.2.2. Behavioral testsBehavior tests were conducted according to our previous
experiments examining nociception and the analgesic effects
of drugs in rodents.15,16 Baseline thermal and mechanical
thresholds were determined before STZ injection and
rechecked every week after the induction of diabetes. Body
weight and blood glucose levels were also measured after the
behavior tests to ensure a persistent hyperglycemic state.2.3. Thermal thresholdsPaw withdrawal latency to radiant heat was used to assess
thermal responses (using a paw stimulator analgesia meter,
model 390; IITC Life Science, Woodland Hills, CA, USA).
Rats were placed in dark plastic cages on a glass platform and
were kept silent and dry for at least 30 minutes. The heat
source was positioned directly beneath the plantar surface
(between the first and second pair of footpads) of the hind
paws and was adjusted to a mean baseline value about 10
seconds with an activated intensity of 25%, and a cutoff time
of 15 seconds to prevent tissue damage. Room temperature
was kept between 22C and 24C. The hind paws were tested
alternately, with at least 8-minute intervals between consecu-
tive tests. A minimum of five tests were performed, and
withdrawal latencies were recorded and averaged.2.4. Mechanical thresholdsMechanical thresholds were measured directly by paw
withdrawal using an electronic von Frey anesthesiometer
(model 2290; IITC Life Science). Rats were transferred to
dark plastic cages with metal mesh bottoms and were allowed
to acclimate for 30 minutes. Gently and gradually increased
pressure was applied with no. 14e16 von Frey filaments from
underneath the metal mesh to the plantar surface of the hind
paws until withdrawal (cutoff ¼ 60 g to prevent tissue
damage). The hind paws were tested alternately with at least
8-minute intervals between consecutive tests. A minimum of
five tests were performed, and the withdrawal pressures were
recorded and averaged.2.5. Animal groups and preparationsIn the first portion of our study, the PGP 9.5 immunoblotted
nerve fiber density in footpad skin sections of Spra-
gueeDawley rats before STZ treatment (baseline) and at 6, 8,
12, 16, and 24 weeks after diabetes was induced, were
measured (n ¼ 5 in baseline and at each time point of dia-
betes). Body weight and blood glucose level at the time point
of study (sacrifice) were also recorded. In the study’s second
portion, STZ-induced diabetic rats were assigned for obser-
vation of the characteristics of painful as well as painless
behaviors as the diabetic duration proceeded until 24 weeks.
Rats with a significant decrease in thermal or mechanical
thresholds compared with baseline values were considered to
have thermal hyperalgesia or mechanical allodynia, respec-
tively. The rats without significant change in either the thermal
or mechanical thresholds were considered to have no presence
of painful behaviors (painless). The rats with significant
increase of thresholds were hypoalgesic.
In the final portion of our study, rats (nS 6 in each group)
at 6e8 weeks after the induction of diabetes from different
behavioral phenotypes (thermal hyperalgesia, group T;
mechanical allodynia, group M; and painless, group N) were
investigated. Controls (C) were body weight matched rats that
received saline.
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in our previous experiments.17,18 In brief, rats were deeply
anesthetized and euthanized with intraperitoneal thiopental at
10 mg/kg, and then a sternotomywas performed to allow needle
cannulation into the left ventricle. Perfusion of 200e250 mL
normal saline was followed by 500 mL 4% paraformaldehyde
through a perfusion pump (MASTERFLEX, Cole-Parmer,
model 7553-70, Vernon Hills, IL, USA). The footpad skin of
the bilateral hind paws was harvested and cryoprotected in
sucrose overnight. Samples were then washed, fixed, and
embedded. Frozen sections were sliced to a thickness of
18e20 mm, with a minimum separation of 80 mm, using an
ultramicrometer (Leica CM3000; Leica Microsystems, Wet-
zlar, Germany) and were stored in phosphate buffer.
Sixteen to 20 sections were selected randomly from each
rat and were mounted on a gelatin-coated slide. Samples were
washed with Tris-buffered solution (pH 7.4), and then 1%
H2O2 was added to remove endogenous peroxidase activity.
Goat serum with 0.5% Triton X-100 was used to block
nonspecific binding. Sections were incubated with the primary
antibody (rabbit anti-PGP 9.5, 1:4000; UltraClone, Yarmouth,
Isle of Wight, UK) at 4C overnight. Controls were incubated
with buffer only (not shown in figures). After rinsing in Tris-
buffered solution, sections were incubated with biotinylated
goat anti-rabbit immunoglobulin G (1:200; Vector, Peter-
borough, UK) at room temperature for 30 minutes, followed
by incubation of the avidinebiotin complex (1:300; Vector)
for another 30 minutes. Subsequently, the reaction products
were visualized with 30,3-diamino-benzidine. Thereafter, the
30,3-diamino-benzidine-stained sections were dehydrated,
counterstained with methyl green, and then coverslipped.2.7. Image analysisEach section was examined under light microscopy by
a trained observer who was blinded to the status of theFig. 1. (A) Microscopic examination of skin sections in rats. The black line encircle
image. Each ROI may comprise one or more papillary dermal and neighborin
bar ¼ 50 mm.) (B) Immunoreactivity measured by a counting grid. The grid is arran
over the image (modified from Yam et al20). The number of squares with nerve fi
innervated by a single protein gene product (PGP) 9.5-stained nerve fiber and neighb
degree of innervation density in the ROI of each section. (Scale bar ¼ 50 mm).sample’s treatment. The region of interest (ROI) was desig-
nated as the papillary dermal and epidermal areas (Fig. 1A).
Five to six representative fields containing one or more ROI at
200 magnification were chosen from each section, and the
digital images were obtained by using a microscopy-based
digital camera system (Microphoto-Fxa; Nikon, Tokyo,
Japan). Image-Pro Plus 4.5 (Media Cybernetics, Silver Spring,
MD, USA) was used to examine the distribution of PGP 9.5-
stained fibers. The PGP 9.5-stained epidermal nerve fiber
density (ENFD) was derived and expressed as fibers/mm.19
Briefly, the length of the epidermal layer along the upper
margin of the stratum corneum in each section was measured,
and the number of epidermal FNEs was counted to calculate
the ENFD. Additionally, PGP 9.5-stained fiber innervation
density in dermal and epidermal area was measured. Because
of the extensive decrease of blotted intensity in diabetic
samples, quantitative analysis was performed by placing
a transparent counting grid (modified from Yam et al20)
arranged in a regular square array (16  12, each square
15  15 mm2), over each image. The number of squares with
nerve fibers was counted and averaged. The resulting value
directly represented the degree of nerve fiber innervation in the
ROI of each skin section (Fig. 1B).2.8. Statistical analysisResults were presented as mean  standard deviation (SD).
For comparing differences, ManneWhitney U-test was used.
3. Results3.1. STZ-induced diabetic rat model and the progressive
loss of skin innervationIn our study, a single injection of 75 mg/kg STZ produced
a persistent hyperglycemic state in more than 90% of subject
rats. The diabetic rats maintained a continuous growth pattern
of body weight until the 8th week, and after that body weightd area represents the range of interest (ROI) in a low magnification field (40)
g epidermal layers, with immunostained fibers extending within it. (Scale
ged in a regular square array (16  12, each square ¼ 15  15 mm2) and placed
bers underling was scored. Note the highlighted squares showing the territory
oring branches (score ¼ 31). The total score of all fibers directly represents the
317C.-C. Chu et al. / Journal of the Chinese Medical Association 75 (2012) 314e321decreased significantly (Fig. 2A). In contrast, those rats that
received saline kept growing, and the body weight rapidly
exceeded 500 g. Hyperglycemia occurred within 1 week
(mean 4.7  1.2 days) after STZ injection, and the uncon-
trolled blood glucose level increased progressively until the
24th week (Fig. 2B). Meanwhile, the blood glucose level of
control rats remained below 270 mg/dL.
In the first portion, the cutaneous nerve density in the
footpad skin sections of diabetic rats decreased significantly at
the 6th week, and then was maintained at the same level for the
following 6 weeks. After this, the density depleted profoundly
until the 24th week (Fig. 2C). The progressive decrease in
cutaneous nerve innervation reflects the background of
extensive nerve degeneration in our animal model.3.2. Painful and painless behavioral phenotypesIn the second portion, the onset of painful behaviors in
diabetic rats varied from 2 to 10 weeks after induction of
diabetes, and the duration of the painful behavior was at least
3 weeks. About half of the rats developed painful behaviors as
early as 6e8 weeks after the induction of diabetes, at which
time the loss of peripheral nerve fibers became prominent.Fig. 2. (A) Body weight changes after streptozotocin (STZ) or saline treatment in
growth pattern of body weight until the 8th week; after that the body weight decr
500 g. Data ¼ mean  standard deviation (SD); n ¼ 5; +: significantly different. (
rats remained below 270 mg/dL but increased rapidly in a few weeks and progress
significantly different. (C) The cutaneous nerve fiber density in diabetic rats at differ
the 6th week, the density decreased significantly and then was maintained at the sa
innervation depleted progressively until the 16th week. Data ¼ mean  SD; n ¼ 5These included: thermal hyperalgesia (Fig. 3A) and mechan-
ical allodynia (Fig. 3B). Moreover, a portion of the animals
did not exhibit significant thermal or mechanical threshold
change (painless, Fig. 3C) in the period. As the diabetic
duration extended past 16 weeks, most of the rats became
hypoalgesic (significant increased in threshold) accompanied
by decreased body weight and activity that implied a decom-
pensated state. There were no significant differences in body
weight and blood glucose levels among the different behav-
ioral types of the diabetic animals.3.3. Depleted FNEs and skin denervation in diabetic ratsIn the skin sections of control rats, there were moderate to
heavily PGP 9.5-stained fibers that were abundant around
sweat glands, which extended continuously into the der-
maleepidermal layers. The epidermal nerve fibers typically
ascended vertically from the dermal papillae into the
epidermal layer, and some radiating branches were also
observed. The mean calculated ENFD was 10.8  2.1 fibers/
mm. The PGP 9.5-stained fibers usually terminated at the
distal end of the dermal papillae, with or without branches.
Some of these terminal fibers form a specialized nervousSpragueeDawley (S-D) rats. The STZ-treated rats maintained a continuous
eased. Control rats continued growing, and the body weight rapidly exceeded
B) Blood glucose level changes in S-D rats. The blood glucose level of control
ively until the 24th week in STZ-treated rats. Data ¼ mean  SD; n ¼ 5, *:
ent time points (baseline, 6, 8, 12, and 16 weeks after induction of diabetes). At
me level for the following 6 weeks. As the duration of diabetes proceeded, the
in each time point; +: significantly different.
Fig. 3. (A) Behavior phenotype of thermal hyperalgesia. Rats showed significant decreases (+: significantly different compared with the baseline values) in thermal
thresholds at 6th to 8th weeks of induced diabetes. After 16 weeks, the threshold increased (*: significantly different compared with the baseline values), and rats
became hypoalgesic to thermal stimuli. Data ¼ mean  SD, n ¼ 6. (B) Behavior phenotype of mechanical allodynia. Diabetic rats showed significant decreases in
mechanical thresholds at 6th to 8th weeks. After 16 weeks, the threshold increased significantly and rats became refractory to mechanical stimuli.
Data ¼ mean  SD, n ¼ 6. +: significantly different compared with the baseline values. (C) Painless behavior phenotype of diabetic rats. Rats in the group
exhibited normal perception, and both thermal and mechanical thresholds remained unchanged at 6th to 8th weeks. After that, most rats became hypoalgesic.
Data ¼ mean  SD, n ¼ 6. *: significantly different compared with the baseline values.
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dermal papillae.
In the diabetic groups T (behavior phenotype of thermal
hyperalgesia), M (mechanical allodynia), and N (painless ¼ no
significant thermal or mechanical threshold change compared
with baseline value), there was a generalized depletion of
epidermal nerve fibers in skin sections (Fig. 4AeD). Occa-
sionally, a single pale, thin stream or dot-like epidermal nerve
fiber could be found under magnification (200). However, no
more than two epidermal fibers could be identified in
a section, and the calculated ENFD was less than 0.1 fiber/
mm. Likewise, the staining intensity of PGP 9.5 in the diabetic
rats was obviously decreased, and the lightly stained fibers
varied in their morphologies as thin or thick, wriggly, and
winding, and most fibers were fragmented. A remarkable
reduction of dermal innervation was also noted, although some
small fibers radiated from a remnant fiber trunk. A near-total
depletion of epidermal and dermal fibers was observed in
some sections in the ROI.
The PGP 9.5 immunodensity score was calculated to
represent the extent of nerve fiber innervation in the skin. This
score was 35.3  2.0 in control samples, but decreased in
diabetic animals to 16.6  0.9 in group T, 22.9  2.6 in group
M, and 20.5  2.2 in group N. Quantitative analysis revealed
a significant decrease in PGP 9.5 immunodensity in all dia-
betic groups. However, there was no statistically significantdifference among the diabetic groups T, M, and N (Fig. 4E).
These results demonstrate the generalized suppression of
nerve fiber innervation in painful and painless diabetic rats.
4. Discussion
The STZ-induced diabetic rat model is widely used in the
study of PDN. The early decreases in thermal and mechanical
thresholds combined with pronounced nerve degeneration in
diabetic rats correspond to the frequently observed painful
symptoms and peripheral nerve fiber depletion in patients with
chronic diabetes.21 It is accepted that STZ at a dosage of
50e60 mg/kg is able to induce a hyperglycemic state by
destroying the pancreatic islet cells. In our study, we used
a dosage of 75 mg/kg to produce a stable and persistent (>16
weeks) hyperglycemic condition, as well as to achieve
a higher rate of induced diabetes (w90%). The complications
that frequently accompany STZ administration, including low
body weight, excessive urination, and infection, were
controlled by strict health screening and optimized housing
conditions. A portion of the rats could remain in a normogly-
cemic state after STZ treatment. Hyperalgesic behavior was
not observed in these animals until 12 weeks after STZ. Direct
cytotoxic effect and neural damage induced by STZ have been
proposed in a recent report.22 However, Pabbidi et al22 used
a different, higher STZ dose (200 mg/kg) with a mouse model,
Fig. 4. Microscopic findings in the region of interest (ROI) in skin sections immunostained with PGP 9.5 to reveal the innervation of intraepidermal and dermal
nerve fibers at 200 magnification. (A) Sections in control rats, which revealed abundant nerve fibers extending from dermal to epidermal layers with abundant
branches. (B) Sections in rats with mechanical allodynia (M); (C) thermal hyperalgesia (T); and (D) painless group (N). Sections BeD revealed an obvious
diminution in nerve fiber innervation. The interrupted, lightly stained residual fibers appeared mainly in the dermal layer with little branching. (Black arrows:
epidermal-free nerve endings; red arrows: residual dermal fibers. Scale bar ¼ 50 mm. PGP 9.5 ¼ protein gene product 9.5.) (E) PGP 9.5 immunoreactivities in
different groups of rats at diabetic weeks 6e8. Significant decreases in PGP 9.5 expression (+) was noted in all diabetic rats (T, M, and N). C ¼ body weight-
matched controls; M ¼ mechanical allodynia; N ¼ painless group; PGP 9.5 ¼ protein gene product 9.5; T ¼ thermal hyperalgesia. (Data ¼ mean  SD, n ¼ 5 in
controls and n ¼ 6e8 in each diabetic group).
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that is recognized in chronic diabetics.
The onset of painful behavior varied from 2 to 10 weeks
after STZ treatment and induced diabetes in our study. During
this pain-genesis period, the rats exhibited a moderate extent
of nerve fiber loss but maintained a stable body weight and
blood glucose level, which implied an underlying regenera-
tion/repair activity in the periphery. After this period, the rats
revealed depleted peripheral nervous innervation andexperienced profound hypoalgesia to external stimuli. The
above nervous regeneration period is reasonably critical to the
development of PDN. The painful diabetic rats collected at 6th
to 8th weeks demonstrated hypersensitivity to peripheral
thermal and/or mechanical stimuli. On the other hand,
a normal “painless” state was also found in some diabetic rats.
Some of these “painless” rats eventually developed PDN, but
in some cases not for 16 weeks. This finding indicates that
there are corresponding pathological changes in the peripheral
320 C.-C. Chu et al. / Journal of the Chinese Medical Association 75 (2012) 314e321nerve degeneration and regeneration, which lead to subsequent
pain genesis. As the duration of the hyperglycemic state
persists, the nerve fiber density depletes progressively, to the
extent that signal transduction is terminated, or nerve
conduction is significantly delayed such that the animals
eventually become hypoalgesic.
It is believed that changes in cutaneous innervation are
more sensitive and may reflect early peripheral neuropathol-
ogies in diabetes.23 One hypothesis of the pain genesis in
diabetic rats is the over-regenerated nerve endings in the
peripheral areas after injury. It could cause a focal increase in
nerve density and lead to peripheral sensitization. Our study
results show the early, progressive depletion of FNEs as well
as a decrease in epidermal and dermal innervation in diabetic
rats, irrespective of the presence of painful behaviors, thus
subverting the above hypothesis. The peripheral sensitization
occurred in a background of generalized cutaneous denerva-
tion. Although these findings are largely compatible with the
recent report that the extent of skin denervation in diabetic
patients increased with diabetic disease duration,19 it revealed
the fact that nerve degeneration alone cannot produce hyper-
algesic or allodynic behavior, as evident by the phenotype of
diabetic rats with no pain symptoms (group N). The depletion
of peripheral-free nerve terminals caused by hyperglycemic-
induced demyelination could be the first neuropathic event
in diabetes. Subsequent neuroplasticity, including activation of
a certain type of neuropeptides, growth factors, or cellular
mediators,24e26 should be the stepwise triggers that induce the
genesis of PDN.
Conventional wisdom dictates that decreased innervation
and depleted FNEs would lead to diminished peripheral
nociceptive input to the spinal cord and have an impact on
proposed underlying spinal or central mechanisms.3 In fact,
complementary evidence that peripheral nociceptor activation
takes place during PDN has been reported.27,28 In our study,
the diabetic rats in the painful groups evidently experienced
hypersensitivity to peripheral thermal or mechanical stimuli,
such that even the painless rats could have transient normal
nociceptive responses. This suggests that the residual dermal
nerve fibers are sufficient to receive and transmit nociception
throughout the epidermal and dermal layers in peripheral
neuropathy. If the residual nociceptive pathway is replaced by
a subset of sensitized fibers and/or neuropeptides, hypersen-
sitivity occurs. A report noting preserved conduction velocity
with C-fiber hyper-responsiveness to mechanical stimuli in
diabetic rats demonstrated by Chen and Levine29 also
confirmed our point of view. Accordingly, sensitization of the
residual fibers produced a hyperalgesic phenotype similar to
animal groups T and M. The other animals without the
sensitization of residual fibers would be normoperceptive, as
in the case of rats in group N.
In conclusion, our study results revealed a generalized
depletion in peripheral nerve innervation in diabetic rats with
or without PDN. The most feasible explanation for this
apparent discrepancy is that peripheral sensitization was
activated by concomitant neuropeptides, growth factors, or
cellular mediators in the residual nerve terminals. Furtherexperiments and observations focus on above activators are
necessary to disclose the pathogenesis of PDN.
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